Vanguard Group
IMNP

Vanguard Group’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Vanguard Group’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-136,841
Closed -$26K – 4202
2018
Q2 		$26K Hold
136,841
– – ﹤0.01% 4119
2018
Q1 		$48K Sell
136,841
-278,677
-67% -$133K ﹤0.01% 4068
2017
Q4 		$237K Buy
415,518
+189,081
+84% +$180K ﹤0.01% 3901
2017
Q3 		$342K Sell
226,437
-3,332
-1% -$5.83K ﹤0.01% 3815
2017
Q2 		$715K Sell
229,769
-19,382
-8% -$52.1K ﹤0.01% 3656
2017
Q1 		$728K Buy
249,151
+50,057
+25% +$181K ﹤0.01% 3665
2016
Q4 		$725K Buy
199,094
+94,898
+91% +$390K ﹤0.01% 3657
2016
Q3 		$584K Buy
104,196
+93,551
+879% +$691K ﹤0.01% 3723
2016
Q2 		$86K Hold
10,645
– – ﹤0.01% 4040
2016
Q1 		$92K Buy
10,645
+3,645
+52% +$37.4K ﹤0.01% 4037
2015
Q4 		$102K Buy
7,000
+3,698
+112% +$77.7K ﹤0.01% 4079
2015
Q3 		$78K Buy
3,302
+1,744
+112% +$54.9K ﹤0.01% 4114
2015
Q2 		$60K Buy
+1,558
New +$61.5K ﹤0.01% 4147

Other funds holding IMNP

IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Vanguard Group's IMNP Position: Q3 2018 in Review

Vanguard Group sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2018, closing a stake of 136,841 shares — an estimated $26K sold.

Vanguard Group first reported a position in IMNP in Q2 2015 and held it in 13 quarters. The position peaked at $728K in Q1 2017. 1 fund tracked by Wall St. Rank holds IMNP as of Q3 2018.

  • Vanguard Group reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Vanguard Group sold 136,841 Immune Pharmaceuticals Inc. shares in Q3 2018, an estimated $26K.
  • Vanguard Group first reported a position in Immune Pharmaceuticals Inc. in Q2 2015 and held it in 13 quarters.
  • Vanguard Group's Immune Pharmaceuticals Inc. position peaked at $728K in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2018.

Based on Vanguard Group's 13F filing for Q3 2018, filed 14 Nov 2018.